Concise Prescribing Info
Infections caused by susceptible microorganisms eg, upper & lower resp tract, skin & soft tissue infections. In combination w/ other antimycobacterials for Mycobacterium avium complex (MAC) infections, H. pylori infection in patient w/ duodenal ulcer.
Dosage/Direction for Use
Adult Mild to moderate resp or skin & soft tissue infections 250 mg every 12 hr for 7-14 days. Mild to moderate acute maxillary sinusitis 500 mg every 12 hr for 14 days. Acute exacerbation of chronic bronchitis caused by H. influenzae 500 mg every 12 hr for 7-14 days. Disseminated MAC infections 500 mg every 12 hr in combination w/ other antimycobacterials. H. pylori infections 500 mg tid for 14 days in combination w/ other drugs. Dual therapy.
May be taken with or without food.
Hypersensitivity to clarithromycin, erythromycin or other macrolides. Co-administration w/ terfenadine, astemizole, cisapride or pimozide.
Special Precautions
Hepatic impairment & moderate to severe renal impairment. Pregnancy (1st trimester) & lactation.
Adverse Reactions
Diarrhea, nausea, vomiting, abnormal taste, dyspepsia, abdominal discomfort. Headache, anxiety, vertigo, insomnia, confusion, bad dreams, hallucination, & transient elevations of liver enzymes. Allergic reactions eg, urticaria, rash & pruritus. Pseudomembranous colitis.
Drug Interactions
May increase serum conc of drugs metabolized by the CYP-450 system, & HMG-CoA reductase inhibitor eg, lovastatin, simvastatin. QT prolongation & serious CV effects may occur w/ cisapride, pimozide, terfenadine, or astemizole. Acute ergot toxicity, vasospasm & ischemia of the extremities & other tissues, including the CNS may occur w/ ergot alkaloids (ergotamine, dihydroergotamine). Carbamazepine. Increased metabolism w/ rifabutin or rifampicin. May potentiate the effects of oral anticoagulants. CNS effects (eg, somnolence, confusion) may occur w/ triazolam. May elevate serum conc of digoxin & theophylline. Increased peak plasma conc & AUC w/ atazanavir. Increased AUC w/ delavirdine. Increased conc w/ fixed combination of lopinavir & ritonavir. Decreased peak plasma conc & AUC w/ efavirenz. Increased plasma conc w/ saquinavir.
MIMS Class
ATC Classification
J01FA09 - clarithromycin ; Belongs to the class of macrolides. Used in the systemic treatment of infections.
Clacina FC tab 500 mg
5 × 14's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in